RxDoctor Payments Data

Jacqueline Murillo, APRN

Gerontology · Middlebury, CTNPI 1962179275

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 47.1% of the total. Among gerontology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,253in general payments, 2019–2025

Across 107 payments — averaging $49.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$649
  • Otsuka America Pharmaceutical, Inc.$524
  • Neurocrine Biosciences, Inc.$316
  • Axsome Therapeutics, Inc.$261
  • Vanda Pharmaceuticals Inc.$260
  • plus $767 from 7 others

What the payments were for

  • Food & beverage$5,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,253 in reported general payments places this provider in the 95th percentile of 90 gerontology providers in Connecticut.

See all gerontology providers in Connecticut

Medicare billing

Part B allowed, 2024
$7,307
Medicare patients
14
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl38$51,721
TrintellixVortioxetine Hydrobromide13$8,186
Fluoxetine Hcl27$1,744
Sertraline Hcl42$455
Venlafaxine Hcl ErVenlafaxine Hcl23$451
Aripiprazole16$387
Hydroxyzine Hcl31$371
Buspirone Hcl28$355
Ziprasidone Hcl15$351
Clonazepam51$336
Bupropion XlBupropion Hcl30$263
Bupropion Hcl SrBupropion Hcl16$248
Risperidone20$236
Mirtazapine35$227
Trazodone Hcl49$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$2,476$51,72138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 gerontology providers in Connecticut.

Other gerontology in Middlebury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →